Keryx Biopharmaceuticals, Inc., a development stage company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. Its endocrine/renal products include Phase III and Phase IV stage Sulonex for diabetic nephropathy; and Zerenex, a Phase II product for hyperphosphatemia in patients with end-stage renal disease. The company’s oncology products comprise KRX-0401, a Phase II product for multiple forms of cancer; KRX-0402, a Phase II product for Brain cancer; and KRX-0404, a preclinical stage product for multiple forms of cancer. Its neurology product, a preclinical stage KRX-0501 is intended to be...